Affilogic and SML Biopharm to Collaborate on Targeted mRNA-LNP Therapeutics

Affilogic and SML Biopharm, a South Korea-based biotech company specializing in mRNA-based therapeutics, have signed a memorandum of understanding (MOU) to collaborate on the development of next-generation targeted drugs using mRNA-LNP (lipid nanoparticle) technology. The agreement aims to integrate Nanofitins with SML Biopharm’s mRNA-LNP platform.

Under the MOU, the two companies will explore opportunities to combine their respective core technologies to develop innovative therapeutics and identify synergies that can drive joint R&D initiatives. SML Biopharm is currently advancing a range of therapeutic and vaccine candidates targeting infectious diseases, rare disorders, and cancer by leveraging its proprietary mRNA expression platform and LNP delivery technology. “We believe this collaboration with Affilogic will significantly broaden the potential applications of our mRNA-LNP platform,” said a representative from SML Biopharm.